Skip to content

Postpartum Intrauterine Device Study

A Pilot Study Of A Randomized Trial Comparing Two Different Time Frames For Copper T380A Intrauterine Contraception Insertion; Immediately Postpartum Compared To 4-6 Weeks Postpartum In Lilongwe, Malawi

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01175161
Acronym
PPIUD
Enrollment
115
Registered
2010-08-04
Start date
2010-10-31
Completion date
2011-06-30
Last updated
2011-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception, Intrauterine Devices, Pilot Study, Africa

Keywords

Postpartum Contraception, Intrauterine device, feasibility, IUD, Immediate postpartum IUD

Brief summary

The purpose of this non-blinded randomized clinical trial is to pilot the design of a randomized clinical trial to be conducted in Malawi to investigate immediate postpartum insertion of the Copper T380 intrauterine contraceptive device (CuT380A-IUCD) compared to placement at the 6-week postpartum visit. The investigators hypothesize that it will be feasible to enroll 140 women into this study, and that women will find the 10 minute to 48 hour time frame for IUCD placement acceptable.

Detailed description

Women will be enrolled into the study during prenatal care. After delivery, if they meet secondary eligibility criteria, they will be randomized to receive the IUD immediately postpartum or at the 6-week postpartum visit. Women will be followed at 4, 8, and 12 weeks after IUD insertion, and be assessed at those time points for satisfaction with the method and IUD expulsion.

Interventions

the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.

Sponsors

University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Primary Inclusion Criteria: * Ages 18-45 attending prenatal care * Greater than 34 weeks estimated gestational age * Desire to use the CuT380A-IUCD for contraception postpartum * Plan to stay in the area for at least 5 months postpartum * If HIV+ the women must be WHO Clinical Stage 1 or 2, or known to be clinically well on antiretroviral therapy as documented in their health passport * No prior cesarean delivery * No treatment for pelvic inflammatory disease within 3 months prior to pregnancy * No known uterine anomalies * No known pelvic tuberculosis * No known genital tract cancer * No known allergy to copper * No known history of ectopic pregnancy within 3 months prior to pregnancy. * No evidence of clinical anemia as assessed by a clinician at enrollment * Any other condition a clinician feels should preclude the woman from receiving the IUCD 10-minutes to 48 hours after delivery Secondary Eligibility Criteria * Vaginal delivery within the last 48 hours * No postpartum hemorrhage documented by the delivering clinician * Not known to have ruptured membranes for greater than 24 hours prior to delivery * No infection diagnosed by a clinician * No fever of greater than 38° during labour or delivery * Any other condition which a clinician feels precludes the woman from receiving the IUCD 10 minutes to 48 hours after delivery.

Exclusion criteria

* prior cesarean section * fever during labor and delivery * AIDS, not well on antiretroviral therapy * genital tuberculosis * known uterine abnormalities or genital tract cancer * history of ectopic pregnancy within 3 months of current pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Time6 monthsEstimate the time required to enroll 140 women into this study

Secondary

MeasureTime frameDescription
Expulsion rates6 monthsEstimate the expulsion rate of the CuT380A-IUCD
Satisfaction6 monthsAssess patient and provider satisfaction when the CuT380A-IUCD is placed 10 minutes - 48-hours postpartum.

Countries

Malawi

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026